Genelux Stock (NASDAQ:GNLX)

Revenue Ownership Financials Chart

Previous Close

$2.52

52W Range

$2.29 - $8.54

50D Avg

$2.82

200D Avg

$3.07

Market Cap

$109.41M

Avg Vol (3M)

$253.97K

Beta

0.56

Div Yield

GNLX Company Profile

Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux maintains its headquarters in Westlake Village, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Jan 26, 2023

Website

GNLX Performance

GNLX Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	$8.00K	$8.00K	$170.00K
Operating Income	-	$-31.70M	$-24.16M
Net Income	$-32.15M	$-29.87M	$-28.30M
EBITDA	-	$-28.97M	$-26.46M
Basic EPS	$-0.86	$-0.95	$-1.16
Diluted EPS	$-0.86	$-0.95	$-1.16

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

Ticker	Company
CTNM	Contineum Therapeutics, Inc.
LXEO	Lexeo Therapeutics, Inc. Common Stock
DRTS	Alpha Tau Medical Ltd
ACIU	AC Immune S.A.
CLLS	Cellectis S.A.
MREO	Mereo BioPharma Group plc
LYEL	Lyell Immunopharma, Inc.
CADL	Candel Therapeutics, Inc.
ALDX	Aldeyra The
SLN	Silence Therapeutics plc